Siddhartha Kadia, Ph.D.
Dr. Siddhartha Kadia previously served as the President of the Life Sciences division at Life Technologies, where he managed $2B P&L which consisted of some of the most recognized brands in the industry. Additionally, Dr. Kadia served as the President and Chief Executive Officer of EAG Laboratories, a global leader for scientific testing and materials analysis across industries from aerospace and agriculture to medical devices and pharmaceuticals. He has been involved in numerous mergers, acquisitions and integrations as a business leader in life sciences and TIC industries. Dr. Kadia has a PhD in Biomedical Engineering from Johns Hopkins University along with a consulting background from McKinsey. He serves on the Board of Overseers for Scripps Research Institute in La Jolla, and on the Commercial advisory board of NSF center for Cell Manufacturing Technologies (CMaT). He also brings significant corporate governance experience with his current service as a director on several public and private company boards such as NuVasive (NSDQ: NUVA), ALS Limited (ASX: ALQ), Applied Technical Services (ATS) and BioSkryb Genomics. He previously served on the boards of Volcano corporation (NSDQ: VOLC), Newport Corporation (NSDQ: NEWP), Horizon Discovery Group (LSE: HZD).